CN105106282A - Drug combination for treating myocardial ischemia reperfusion of rats - Google Patents
Drug combination for treating myocardial ischemia reperfusion of rats Download PDFInfo
- Publication number
- CN105106282A CN105106282A CN201510536781.0A CN201510536781A CN105106282A CN 105106282 A CN105106282 A CN 105106282A CN 201510536781 A CN201510536781 A CN 201510536781A CN 105106282 A CN105106282 A CN 105106282A
- Authority
- CN
- China
- Prior art keywords
- radix rhodiolae
- quercetin
- medicine
- pharmaceutical composition
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a drug combination for treating myocardial ischemia reperfusion of rats. The drug combination is composed of 10-0 part of rhodiola rosea extract, 0-10 parts of quercetin and 5-5 parts of rhodiola rosea extract and quercetin. The drug combination of rhodiola rosea extract and quercetin has protecting effect on rat myocardial cell injury caused by myocardial ischemia and reperfusion, and a theoretical basis is provided for preventing and treating myocardial infarction and for developing and utilizing a quercetin and rhodiola mixture clinically.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition preventing and treating myocardial infarction, be specifically related to a kind of pharmaceutical composition for the treatment of rat myocardial ischemia and reperfusion.
Background technology
Myocardial infarction sickness rate and disability rate are all higher, are one of three large diseases threatening human health.Research shows, the necrosis of neurocyte not only occurs after myocardial ischemia, around ischemic region, due to the foundation of impaired comparatively light and Doppler flow mapping, can produce DNA damage and apoptosis-induced.The present invention's research is in rat model of myocardial infarction; observation Quercetin and Radix Rhodiolae mixture are to the protective effect of ischemia/reperfusion injury rat hippocampus DNA and RNA; be intended to inquire into the protective effect that Quercetin and Radix Rhodiolae mixture cause rat myocardial cell damage to Ischemic/reperfusion, prevent and treat for clinical myocardinal infarction and the exploitation of Quercetin and Radix Rhodiolae mixture provide theoretical foundation.
Summary of the invention
In order to overcome the above-mentioned technical problem that prior art exists, the present inventor after having carried out a large amount of further investigations, thus provides a kind of pharmaceutical composition for the treatment of rat myocardial ischemia and reperfusion.
The present invention is achieved through the following technical solutions, a kind of pharmaceutical composition for the treatment of rat myocardial ischemia and reperfusion, composed of the following components:
Radix Rhodiolae extract: 10-0 weight portion;
Quercetin: 0-10 weight portion.
Preferably, described pharmaceutical composition is composed of the following components:
Radix Rhodiolae extract: 5 weight portions;
Quercetin: 5 weight portions.
Preferably, described Radix Rhodiolae extract adopts following methods to obtain:
Step one, by 100g Radix Rhodiolae rhizome grind into powder;
Step 2, the heating of described powder water flooded, dipping point carries out for 3 times, and 3 weight that adds water is respectively 10 times, 6 times and 4 times of described Radix Rhodiolae rhizome weight; Extracting temperature is 80 DEG C, each extraction time 100min, merges 3 extracting solution;
Step 3, vacuum 0.085MPa sucking filtration, the centrifugal 10min of 10000rpm, obtains Radix Rhodiolae Aqueous extracts, and decompression rotary evaporation, is settled to 1000mL with water, obtains and has fragranced, thick reddish tan liquid, be Radix Rhodiolae extract.
Compared with prior art; beneficial effect of the present invention is as follows: the compositions of Radix Rhodiolae extract provided by the invention and Quercetin causes rat myocardial cell damage to have protective effect to Ischemic/reperfusion, for the exploitation of the control of clinical myocardinal infarction and Quercetin and Radix Rhodiolae mixture provide theoretical foundation.
Accompanying drawing explanation
By reading the detailed description done non-limiting example with reference to the following drawings, other features, objects and advantages of the present invention will become more obvious:
Fig. 1 is the LVSP result figure that cardiac function of the present invention detects;
Fig. 2 is the LVEDP result figure that cardiac function of the present invention detects;
Fig. 3 is that cardiac function of the present invention detects+dp/dt (max) result figure;
Fig. 4 is the SOD vigor result figure of biochemistry detection of the present invention;
Fig. 5 is the ROS content results figure of biochemistry detection of the present invention;
Fig. 6 is infarct size measurement result figure of the present invention;
Fig. 7 is the TNF-α concentration results figure that ELISA of the present invention detects;
Fig. 8 is the IL-1b content results figure that ELISA of the present invention detects;
Fig. 9 is transmission electron microscope testing result figure of the present invention;
Figure 10 is that the present invention inquires into Radix Rhodiolae extract and Quercetin to the improvement experiment process figure of myocardial ischemia reperfusion injury.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is described in detail.Following examples will contribute to those skilled in the art and understand the present invention further, but not limit the present invention in any form.It should be pointed out that to those skilled in the art, without departing from the inventive concept of the premise, some distortion and improvement can also be made.These all belong to protection scope of the present invention.
The process of the test that the present invention adopts comprises the following steps, as shown in Figure 10:
The first step: the extraction of Radix Rhodiolae, the dissolving of Quercetin, obtains the mixture of Quercetin and Radix Rhodiolae extract different ratio;
Second step: ami model is set up;
3rd step: cardiac function detects;
4th step: biochemistry detection
5th step: infarct size measures;
6th step, transmission electron microscope detects;
The preparation of embodiment 1, Radix Rhodiolae extract and Quercetin different ratio mixture
The leaching process of Radix Rhodiolae: by 100g Radix Rhodiolae rhizome grind into powder; The heating of above-mentioned powder water flooded, dipping point carries out for 3 times, and 3 weight that adds water is respectively 10 times, 6 times and 4 times of Radix Rhodiolae rhizome weight; Extracting temperature is 80 DEG C, each extraction time 100min, merges 3 extracting solution; Vacuum 0.085MPa sucking filtration, the centrifugal 10min of 10000rpm, obtains Radix Rhodiolae Aqueous extracts, decompression rotary evaporation, with water standardize solution 1000mL, obtains and has fragranced, thick reddish tan liquid, be Radix Rhodiolae extract, in extract, the concentration of contained crude drug amount is 0.1g/mL.
Radix Rhodiolae extract and Quercetin different ratio: adopt weight ratio 10:0,5:5 and 0:10 of Radix Rhodiolae extract and Quercetin to carry out evaluating drug effect, after extract water or 0.5% sodium carboxymethyl cellulose can being suspended, gastric infusion, the maximum administration volume of rat can not more than 4mL.
Embodiment 2, cardiac function detect
| LVSP(mmHg) | LVEDP(mmHg) | +dp/dt(max)(mmHg/s) | -dp/dt(min)(mmHg/s) | |
| Sham-operation | 151.33±31.24 | 4.115±2.48 | 7619.12±2013.21 | -5387.33±1868.715 |
| MI+ normal saline | 74±25.73* | 18.06±6.21* | 3719.3±1520.71* | -2847.67±737.43* |
| MI+ medicine 1 | 101±20.57* | 12.11±3.01* | 4592.03±1512.11* | -3751.33±970.49 |
| MI+ medicine 2 | 123±21.88* | 9.02±3.13* | 6041±1760.43* | -3888.83±1355.56 |
| MI+ medicine 3 | 131.83±17.03* | 8.04±3.01* | 6591.83±2150.88* | -4321.17±1252.08 |
Remarks: medicine 1:(Radix Rhodiolae/Quercetin=10:0), medicine 2:(Radix Rhodiolae/Quercetin=0:10), medicine 3:(Radix Rhodiolae/Quercetin=5:5)
Learn from the result shown in Fig. 1, Fig. 2 and Fig. 3, the numerical value of the LVPS that medicine is 3 groups and+dp/dt (max) is all significantly higher than medicine 1 and medicine 2 groups, and the numerical value of the LVEDP that medicine is 3 groups is all remarkable in medicine 1 and medicine 2 groups.
Embodiment 3, biochemistry detection
Learn from the result shown in Fig. 4 and Fig. 5, the numerical value of the SOD vigor of medicine 3 groups is all significantly higher than medicine 1 and medicine 2 groups, and the numerical value of the LVEDP that medicine is 3 groups is all remarkable in medicine 1 and medicine 2 groups.
Embodiment 4, infarct size measure
Learn from the result shown in Fig. 6, the numerical value of the infarction ratio of medicine 3 groups is all remarkable in medicine 1 and medicine 2 groups, and the numerical value of the infarction ratio of medicine 1 group is all significantly higher than medicine 2.
Embodiment 5, ELISA detect
Learn from the result shown in Fig. 7 and Fig. 8, the numerical value of TNF-a and IL-1b that medicine is 3 groups is all remarkable in medicine 1, medicine 2 and medicine 3 group difference little.
Embodiment 6, transmission electron microscope detect
Result is as shown in Figure 9 known, and sham operated rats myocardial cell form is complete, cardiac muscle bundle marshalling; Model group+normal saline myocardial cell form is destroyed, and cardiac muscle bundle disappears; The visible cardiac muscle bundle of MI+ medicine 1 group; MI+ medicine 2 myocardial cell form is more complete; The visible cardiac muscle bundle of MI+ medicine 3, myocardial cell form is more complete, and medicine 3 best results is described.(remarks: medicine 1:(Radix Rhodiolae extract/Quercetin=10:0), medicine 2:(Radix Rhodiolae extract/Quercetin=0:10), medicine 3:(Radix Rhodiolae extract/Quercetin=5:5))
Above specific embodiments of the invention are described.It is to be appreciated that the present invention is not limited to above-mentioned particular implementation, those skilled in the art can make various distortion or amendment within the scope of the claims, and this does not affect flesh and blood of the present invention.
Claims (3)
1. treat a pharmaceutical composition for rat myocardial ischemia and reperfusion, it is characterized in that, composed of the following components:
Radix Rhodiolae extract: 10-0 weight portion;
Quercetin: 0-10 weight portion.
2. pharmaceutical composition as claimed in claim 1, is characterized in that, described pharmaceutical composition is composed of the following components:
Radix Rhodiolae extract: 5 weight portions;
Quercetin: 5 weight portions.
3. pharmaceutical composition as claimed in claim 1 or 2, is characterized in that, described Radix Rhodiolae extract adopts following methods to obtain:
Step one, by 100g Radix Rhodiolae rhizome grind into powder;
Step 2, the heating of described powder water flooded, dipping point carries out for 3 times, and 3 weight that adds water is respectively 10 times, 6 times and 4 times of described Radix Rhodiolae rhizome weight; Extracting temperature is 80 DEG C, each extraction time 100min, merges 3 extracting solution;
Step 3, vacuum 0.085MPa sucking filtration, the centrifugal 10min of 10000rpm, obtains Radix Rhodiolae Aqueous extracts, and decompression rotary evaporation, is settled to 1000mL with water, obtains and has fragranced, thick reddish tan liquid, be Radix Rhodiolae extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510536781.0A CN105106282A (en) | 2015-08-27 | 2015-08-27 | Drug combination for treating myocardial ischemia reperfusion of rats |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510536781.0A CN105106282A (en) | 2015-08-27 | 2015-08-27 | Drug combination for treating myocardial ischemia reperfusion of rats |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105106282A true CN105106282A (en) | 2015-12-02 |
Family
ID=54654564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510536781.0A Pending CN105106282A (en) | 2015-08-27 | 2015-08-27 | Drug combination for treating myocardial ischemia reperfusion of rats |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105106282A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106310228A (en) * | 2016-11-03 | 2017-01-11 | 河北大学 | Medicine compound for treating myocardial ischemia reperfusion of rat and application method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1931217A (en) * | 2005-09-14 | 2007-03-21 | 蔡军 | Medicine composition of gingko leaf and rhodiola root |
| CN1977890A (en) * | 2005-11-29 | 2007-06-13 | 江苏中康药物科技有限公司 | Chinese medicine composition and its use |
-
2015
- 2015-08-27 CN CN201510536781.0A patent/CN105106282A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1931217A (en) * | 2005-09-14 | 2007-03-21 | 蔡军 | Medicine composition of gingko leaf and rhodiola root |
| CN1977890A (en) * | 2005-11-29 | 2007-06-13 | 江苏中康药物科技有限公司 | Chinese medicine composition and its use |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106310228A (en) * | 2016-11-03 | 2017-01-11 | 河北大学 | Medicine compound for treating myocardial ischemia reperfusion of rat and application method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hamid et al. | Amelioration of CCl4-induced liver injury in rats by selenizing Astragalus polysaccharides: Role of proinflammatory cytokines, oxidative stress and hepatic stellate cells | |
| CN101180069B (en) | Herbal compositions useful in cancer treatment | |
| K Chellappan et al. | The protective action of the aqueous extract of Auricularia polytricha in paracetamol induced hepatotoxicity in rats | |
| Lima et al. | In vivo effects of cagaita (Eugenia dysenterica, DC.) leaf extracts on diarrhea treatment | |
| CN109662983A (en) | Both A. absinthium extract is preparing the application in medicines resistant to liver cancer | |
| CN102215851A (en) | Anti-influenza viral composition containing bark or stem extract of alnus japonica | |
| Gunjan et al. | Pharmacognostic and antihyperglycemic study of Coccinia indica | |
| TW201628637A (en) | Tie2 activator containing olive fruit extract | |
| CN105106282A (en) | Drug combination for treating myocardial ischemia reperfusion of rats | |
| CN103211957B (en) | Alcohol relieving and liver protecting composition and application thereof | |
| CN104825402B (en) | A kind of medicinal composition for injections containing gemcitabine | |
| CN104324317B (en) | A kind of Chinese medicine composition and medical usage for treating fibroid | |
| Abudayyak | In vitro evaluation of Rheum ribes induced genotoxicity in HepG2 cell lines | |
| Shahik et al. | In vitro thrombolytic and cytotoxic evaluation of Mentha arvensis L., Mentha spicata L. and Mentha viridis L. | |
| CN104771745A (en) | Traditional Chinese medicine composition for treating diarrhea, preparation method and application thereof | |
| Nagadesi et al. | Taxonomy and Bioactive chemicals from Ganoderma and Phellinus of India | |
| CN104922268B (en) | A kind of method that active material is extracted from natural plants | |
| CN104887812B (en) | A kind of drug effectively antagonizing porcine reproductive and respiratory syndrome virus and preparation method thereof and application method | |
| CN104096150B (en) | Stahlianthus hainanensis (Hayata) T. L. Wu and its extract are preparing treatment and/or the application of prevention cancer drug | |
| Ozims et al. | Effect of aqueous leaf extract of Cymbopogon citratus (Lemcngrass-Achara tea) on liver function in paracetamol-induced hepatotoxicity in albino rats | |
| CN102670735A (en) | Anti-dandruff Chinese medicinal composition and application thereof to anti-dandruff external application agent | |
| Venkateswarlu | In vitro stability testing of syrup dosage form for hepatitis | |
| CN107233335A (en) | Perillaldehyde is preparing the purposes in preventing and treating the medicine of vaginitis | |
| CN102512463A (en) | Extraction method of nettle extract | |
| CN101167771A (en) | Application of vinca flower and its extraction in preparing medicine for resisting AIDS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170927 Address after: 201100 No. 3589, 671 North Pine Road, Shanghai, Minhang District Applicant after: SHANGHAI USEN BIOLOGICAL TECHNOLOGY CO., LTD. Address before: 201599 Shanghai city Jinshan District zhujingzhen Street No. 18 building 26 room 216 Applicant before: SHANGHAI YOUSHEN BIOTECHNOLOGY CO., LTD. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151202 |
|
| RJ01 | Rejection of invention patent application after publication |